Neumentum Enters into Global Licensing Agreement for a Novel Class of Investigational Pain Treatments

by Sky Striar | Oct 10, 2019 | Press Releases

Agreement significantly expands Neumentum’s pipeline of investigational pain therapies aimed at addressing the growing need for innovative analgesics  PALO ALTO, Calif., October 10, 2019 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain...

Neumentum Presents Data on Lead Product Candidate NTM-001 at PAINWeek 2019

by Sky Striar | Sep 5, 2019 | Press Releases

Neumentum’s poster presentations #39, #40, #41 and #42 from PAINWeek are now available to view.   – Results Support What Has the Potential To Be the First-Ever Non-Steroidal Anti-Inflammatory (NSAID) Approved for Continuous Infusion – Results Confirm...

Neumentum Phase I Study Confirms Its Non-Opioid in Development for Moderately Severe Acute Pain, NTM-001, Performs in Healthy Adults as Predicted

by Sky Striar | Jan 7, 2019 | Press Releases

– The Phase I Clinical Study of a Continuously Infused NSAID, NTM-001, Provided Steady Plasma Levels of Ketorolac Over 24 Hours, With No Unexpected Adverse Effects – Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion Has the...

Neumentum Announces Dosing of Patients in Phase I Study Evaluating Its Lead Product Candidate, NTM-001, a Non-Opioid in Development for the Management of Moderately Severe Acute Pain

by admin | Sep 6, 2018 | Press Releases

– Potential to be the First Continuously Infused NSAID to be Successfully Developed for Acute Post-Operative Pain in the US – NTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion with the...

Neumentum Announces Dosing of Patients in Phase I Study

by admin | Sep 6, 2018 | Press Releases

Neumentum Announces Dosing of Patients in Phase I Study Evaluating Its Lead Product Candidate, NTM-001, a Non-Opioid in Development for the Management of Moderately Severe Acute Pain.

Neumentum Confirms Type B Meeting with FDA and Announces New Chief Medical and Scientific Officers

by admin | Feb 26, 2018 | Press Releases

— May 8 Type B meeting confirmed to discuss the clinical development program for lead product candidate NTM-001, which has potential to treat moderately severe acute postoperative pain that requires analgesia at the opioid level, reducing the need for opioids in...